Cambridge Investment Research Advisors Inc. Purchases 1,452 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Cambridge Investment Research Advisors Inc. boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 87.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,119 shares of the company’s stock after acquiring an additional 1,452 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Medpace were worth $663,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Wasatch Advisors Inc. raised its holdings in Medpace by 12.1% in the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock valued at $446,338,000 after acquiring an additional 294,103 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Medpace by 2,058.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 287,194 shares of the company’s stock worth $45,138,000 after purchasing an additional 273,887 shares during the period. Thrivent Financial for Lutherans boosted its stake in Medpace by 2,043.7% during the third quarter. Thrivent Financial for Lutherans now owns 151,385 shares of the company’s stock worth $23,793,000 after buying an additional 144,323 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Medpace by 32.4% during the second quarter. Goldman Sachs Group Inc. now owns 390,038 shares of the company’s stock worth $58,377,000 after buying an additional 95,524 shares in the last quarter. Finally, Channing Capital Management LLC increased its holdings in Medpace by 45.3% in the 3rd quarter. Channing Capital Management LLC now owns 231,460 shares of the company’s stock valued at $36,379,000 after buying an additional 72,149 shares during the period. 82.49% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Friday, May 12th. Guggenheim upgraded Medpace from a “neutral” rating to a “buy” rating and set a $252.00 price objective on the stock in a research note on Monday, May 8th. 22nd Century Group restated an “upgrade” rating on shares of Medpace in a research report on Monday, May 8th. Finally, Robert W. Baird upped their price target on Medpace from $226.00 to $233.00 and gave the company a “neutral” rating in a research report on Wednesday, February 15th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $241.00.

Medpace Trading Down 1.8 %

NASDAQ MEDP opened at $205.69 on Wednesday. Medpace Holdings, Inc. has a 1-year low of $130.38 and a 1-year high of $241.48. The company has a 50 day moving average of $194.67 and a 200-day moving average of $206.83. The firm has a market cap of $6.27 billion, a price-to-earnings ratio of 26.53 and a beta of 1.42.

Medpace (NASDAQ:MEDP – Get Rating) last released its quarterly earnings results on Monday, April 24th. The company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.76 by $0.51. The firm had revenue of $434.07 million during the quarter, compared to analysts’ expectations of $402.83 million. Medpace had a return on equity of 75.20% and a net margin of 16.44%. The business’s revenue was up 31.2% on a year-over-year basis. During the same period last year, the firm posted $1.69 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 8.11 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 31,648 shares of the firm’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $221.83, for a total value of $7,020,475.84. Following the completion of the sale, the chief executive officer now owns 6,451,371 shares in the company, valued at approximately $1,431,107,628.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 25.70% of the stock is owned by corporate insiders.

Medpace Profile

(Get Rating)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.